Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2015-08-07

FDA Approved: PRIFTIN — Supplemental Application (sanofi-aventis U.S. LLC)

View source ↗

Summary

FDA approved a supplemental application for PRIFTIN (rifapentine) submitted by Sanofi-Aventis U.S. LLC to update the product labeling. The update relates to rif…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Priftin (rifapentine)

Snippet

SUPPL AP for PRIFTIN (RIFAPENTINE)